IBD Archives - Page 2 of 2 - The British Society of Gastroenterology

Clinical Trials

First published on 06 Aug 2018

ASTIClite trial

ASTIClite – Autologous Stem cell Transplantation In refractory Crohn’s disease – Low Intensity Therapy Evaluation The ASTIClite trial aims to assess whether stem cell transplantation, with a low intensity treatment regimen, can reduce the symptoms and activity of Crohn’s disease […]

Clinical Trials

First published on 11 Oct 2017

IASO trial of anakinra for acute severe ulcerative colitis

Despite huge progress in the outpatient management of ulcerative colitis, there are still around 2,500 admissions for acute severe UC in the UK every year. Our current standard initial therapy (intravenous corticosteroids) is based upon the landmark trial of Truelove […]

Clinical Trials

First published on 09 Oct 2017

Crohn’s Disease trial funding success: cine MRI

Joint collaborations between members of the British Society of Gastrointestinal and Abdominal Radiology (BSGAR) and the BSG have led to recent grant success from the NIHR. Led by Prof Stuart Taylor and Dr Andrew Plumb, the team has been awarded £895,292 […]

Guidance

First published on 26 Aug 2015

Vedolizumab for the treatment of adult patients with moderately to severely active Crohn’s disease

Vedolizumab (Entyvio) is recommended. It is a possible option for adults with moderate to severe Crohn’s disease if a tumour necrosis factor (TNF)-alpha inhibitor isn’t suitable or hasn’t worked well enough. People should be able to have vedolizumab until it […]

Guidance

First published on 05 Jun 2015

NICE Guidance on vedolizumab for treating moderately to severely active ulcerative colitis

June 2015 Vedolizumab (Entyvio) is recommended by NICE as a possible treatment for adults with moderate to severe ulcerative colitis. People should be able to have the treatment until it stops working or surgery is needed. Their condition should be […]

Guidance

First published on 25 Feb 2015

Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy

February 2015 Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262) Infliximab (also known as Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) […]

Guidance

First published on 01 Oct 2013

NICE Diagnostics Guidance: Faecal Calprotectin Diagnostic Tests for IBD

Faecal calprotectin testing is recommended as an option to support clinicians with the differential diagnosis of inflammatory bowel disease (IBD) or irritable bowel syndrome (IBS) in adults with recent onset lower gastrointestinal symptoms for whom specialist assessment is being considered, […]

Guidelines

First published on 25 Sep 2013

BSG guidelines on inflammatory bowel disease biopsies

Professor Roger M Feakins Accurate histopathological assessment of biopsies is important for the diagnosis, subclassification, and management of chronic idiopathic inflammatory bowel disease (IBD). British Society of Gastroenterology (BSG) guidelines for the initial histopathological diagnosis of IBD were published in […]

Guidelines

First published on 01 Jun 2013

Ulcerative colitis: management

This guideline covers the care and treatment of adults, children and young people who have ulcerative colitis (UC). It aims to help professionals to provide consistent high-quality care and it highlights the importance of advice and support for people with […]

Guidelines

First published on 01 Oct 2012

Crohn’s disease: management

This guideline covers the management of Crohn’s disease in children, young people and adults. It aims to reduce people’s symptoms and maintain or improve their quality of life.